The company reported $35.0 million in revenues, driven by higher adoption of its molecular information solutions.
The Index fell less than 1 percent in July, underperforming the Dow, the Nasdaq, and the Nasdaq Biotechnology Index.
The law firm alleges that the company misled investors about its progress in obtaining Medicare reimbursement for its cancer genomic tests.
Foundation Medicine's SmartTrials Precision Enrollment program will ID patients with HRAS mutant squamous cell carcinoma of the head and neck.
Guardant is alleging that Foundation's advertising of its own products has harmed both Guardant and cancer patients.
The companies will perform tumor profiling to identify patients with genetic abnormalities that could make them eligible for treatment in the NCI study.
The companies believe the database can facilitate outcomes research, improve variant interpretations, inform drug development efforts.
The registry collects data on cancer genetics and aims to provide patients with access to quality NGS testing, among other things.
There are now 100 sites in the US participating in the basket study, and soon trials with similar approaches will be available in Canada and 13 other countries.
The belief among genomics experts that one day drugs would be given based on genomic abnormalities that cut across tumor types became reality this week.
The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.
A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.
Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.
In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.